Mold-Tek Packaging Limited — Investor Meet, 12-11-2024: Analysts/Institutional Investor Meet/Con. Call Updates

1. **Financial Performance**: In Q2 FY25, Mold-Tek Packaging reported a 7% year-over-year increase in sales volumes, leading to a 6.9% overall growth comparison for Q2. However, due to heightened depreciation and interest costs from significant investments over the past 2.5 years, the profit after tax (PAT) declined by approximately 10% year-over-year. EBITDA increased by 4.5% in Q2, reaching Rs. 36.73 per kg, driven by improved efficiencies and a favorable product mix. Revenue from the paint segment rose by 14%, while the lubricants segment saw almost no growth.

2. **Future Outlook and Growth Drivers**: Management emphasized plans to expand capabilities in the paint and pharmaceutical segments, particularly through ongoing projects with major clients like Aditya Birla Group and new product launches in pharma. The company aims for double-digit overall volume growth for the full year despite a slightly reduced forecast.

3. **Order Book and Operational Updates**: The order book remains strong with increased demand from the pharmaceutical segment, contributing approximately Rs. 75 lakhs in October alone. Capacity utilization at certain plants is on the rise, with projections of 70% utilization for the paint segment in H2 FY25. Management expects the new facility in Mahad to contribute significantly once operational.

4. **Analyst Q&A Insights**:

- **Revenue and Profitability**: Analysts sought clarity on the variance in profitability and revenues, with management attributing profit declines to increased operational costs and the ramp-up phases of new projects.

- **Market Position and Competitive Landscape**: Queries about competition revealed that while pressure exists, especially in paint, Mold-Tek’s focus remains on unique product capabilities, particularly in pharmaceutical packaging.

- **Operational Challenges or Risks**: Discussions about potential delays in approvals and supply chain challenges were met with assurances from management about their ongoing strategies to mitigate risks.

- **Capex and Capital Allocation**: Management confirmed a capex guidance close to Rs. 90 crores for the year, with significant investments earmarked for enhancing pharmaceutical capabilities.

- **Strategic Priorities and Long-Term Vision**: Long-term, management expressed confidence in capturing more market share in the pharma segment, with expectations of reaching Rs. 30-50 crores from this vertical in FY26.

5. **Market or Regulatory Updates**: There were no significant regulatory concerns mentioned, but management noted a competitive landscape and market expansion opportunities, especially in the pharma vertical.

6. **Strategic Focus Areas**: Key themes include innovation in product development, ramping up production efficiencies, and focused growth in pharmaceuticals and FMCG packaging, highlighting an optimistic yet cautious market sentiment.

7. **Investor Insight**: Overall, Mold-Tek's financial health and strategic direction suggest a ‘buy’ position, driven by its expansion plans and projected improvements in profitability, particularly as new capacities come online and sales increase. However, potential risks remain in operational execution and market competition.